CGC - Canopy Growth Corporation

NYSE - NYSE Delayed Price. Currency in USD
48.25
+3.69 (+8.28%)
At close: 4:00PM EDT

48.09 -0.16 (-0.33%)
After hours: 6:30PM EDT

Stock chart is not supported by your current browser
Previous Close44.56
Open45.90
Bid48.10 x 800
Ask48.14 x 1800
Day's Range45.07 - 48.70
52 Week Range20.99 - 59.25
Volume11,865,865
Avg. Volume7,569,345
Market Cap16.652B
Beta (3Y Monthly)3.99
PE Ratio (TTM)N/A
EPS (TTM)-1.79
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Cannabis M&A activity booms despite regulatory hurdles
    CNBC Videos4 hours ago

    Cannabis M&A activity booms despite regulatory hurdles

    Matt Hawkins of Cresco Capital Partners and Michael Lavery of Piper Jaffray discuss M&A activity in the cannabis space on CNBC's " Squawk on the Street."

  • Why Zoom Video Communications, KeyW Holding, and Canopy Growth Jumped Today
    Motley Fool2 hours ago

    Why Zoom Video Communications, KeyW Holding, and Canopy Growth Jumped Today

    Strong momentum continued over the weekend for many stocks even in a mixed market.

  • A Big Deal Reignites Cannabis Stocks
    Zacks3 hours ago

    A Big Deal Reignites Cannabis Stocks

    A Big Deal Reignites Cannabis Stocks

  • Canopy Growth leads cannabis stocks higher after GMP upgrades to buy
    MarketWatch4 hours ago

    Canopy Growth leads cannabis stocks higher after GMP upgrades to buy

    Cannabis stocks were mostly higher on Monday, with Canopy Growth Corp. enjoying gains after two bullish analyst notes and CannTrust Holdings Inc. falling on news it plans to issue another $200 million in stock.

  • Canopy Growth Upgraded on Hope: U.S. Marijuana Legalization by 2027?
    Motley Fool4 hours ago

    Canopy Growth Upgraded on Hope: U.S. Marijuana Legalization by 2027?

    Analyst sees "high likelihood" of federal legalization.

  • ACCESSWIRE5 hours ago

    Investors Should Be Paying Close Attention to This Industry

    CORAL GABLES, FL / ACCESSWIRE / April 22, 2019 / Investors should be paying close attention to the cannabis industry right now. Currently, recreational marijuana is now legal in 10 US states & medical marijuana is legal in 33 US States. Today we are highlighting: Canopy Growth Corporation (CGC) / (TSX:WEED.TO), Aphria Inc. (APHA), Aurora Cannabis Inc. (ACB), Leafbuyer Technologies, Inc. (LBUY).

  • Barrons.com5 hours ago

    Canopy Growth’s New Marijuana Deal Is a Winner for Constellation Brands

    The alcoholic-beverage company owns 38% of Canopy Growth, which agreed to buy the U.S. pot seller Acreage Holdings once cannabis becomes legal under U.S. law.

  • Benzinga6 hours ago

    GMP Upgrades Canopy Growth To Buy Following Acreage Deal

    Cannabis stocks were mostly higher Monday after Canopy Growth Corp (NYSE: CGC ) received positive coverage from an analyst. The Analysts GMP Securities' Martin Landry upgraded Canopy Growth from Hold to ...

  • Barrons.com7 hours ago

    Canopy Growth Stock Is Surging Because a New Deal Could Make It a Big U.S. Marijuana Player

    Acreage Holdings owns 87 dispensaries and 22 cultivation and processing sites in the U.S. and has $300 million cash.

  • After the Drama, Where Is Aphria Headed Now?
    InvestorPlace8 hours ago

    After the Drama, Where Is Aphria Headed Now?

    Even in a space with as much excitement as marijuana stocks, Aphria (NYSE:APHA) stood out for having as much drama as a cable TV show. If you're a trader, APHA stock has been a dream lately. The stock rocketed from $8 to $16 in a month last summer. It then lost as much as 75% of its value, plummeting to $4, after a series of short seller reports. Since then, the stock has bounced 150% off the lows to return to the $10 level, before earnings sent it falling once more.Source: Shutterstock After all the excitement, what's next for APHA stock? And have the company's recent moves made it investable again, or is Aphria only appropriate for the most steel-nerved traders? Fallout From the Bearish Short Seller's ReportsA few months ago, short sellers hit APHA stock with heavy fire. Bearish analysts published reports suggested that Aphria's management had engaged in unscrupulous behavior.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe short sellers suggested that Aphria was engaged in all sorts of questionable if not worse activity. The short sellers said that the company had bought phantom assets in Latin America, engaged in various double-dealing and related party transactions, and numerous other red flags.Aphria's board of directors engaged an independent special committee to investigate the accusations. The special committee found some troubling factors, but its results also exonerated the company in various ways. Arguably the most important finding was that the committee confirmed that Aphria's Latin American assets in fact exist and are progressing toward commercial activity. * 7 Tech Stocks With Too Much Risk, Not Enough Upside The committee suggested that Aphria paid near the top end of a reasonable price range for the assets, but that there is a real business there, unlike the short seller's reports which had claimed these transactions were largely imaginary. New Management for APHA StockHowever, Aphria wasn't blameless either. The board disclosed that: "it appears that certain of the non-independent directors of the Company had conflicting interests in the Acquisition that were not fully disclosed to the Board."Probably in conjunction with that, Aphria has seen major management changes. Former Aphria CEO Vic Neufeld has stepped down, as well as Co-founder Cole Cacciavillani. Neufeld in particular was implicating in several of the alleged misdeeds that the short sellers identified.In his place, Aphria has appointed an interim CEO. Irwin Simon is now in charge, at least for the time being. Simon led Hain Celestial (NASDAQ:HAIN) for more than two decades, helping that company take a dominant position in the natural and organic foods space. While it is obviously a weak spot for Aphria not to have a permanent CEO in place yet, Simon seems to have capable hands to manage the company while it recovers from the reputational blows it suffered recently. Aphria Has a Rough Earnings ReportAs William White pointed out, Aphria plummeted on April 15 after an earnings report "with losses per share of 20 Canadian cents. This is a drop from the company's earnings per share of 8 Canadian cents from the same time last year. It was also bad news for APHA stock by missing analysts' losses per share estimate of 4.5 Canadian cents for the quarter."Revenue was up, but overall sales numbers fell. The market was unimpressed, and the stock is now down around 24% since the report.Back in December, new upstart cannabis firm Green Growth Brands (OTCMKTS:GGBXF) bid to acquire Aphria. This was a highly unusual deal for several reasons. Among them, Green Growth brands itself had just gone public as the merger of several other firms. Additionally, Aphria had a significantly larger market cap than Green Growth, making it a rather odd target for a takeover offer.After the earnings tumble, Green Growth stepped away from their takeover attempt. It may be good for Aphria that another element of uncertainty is gone, but it's hardly unequivocal good news overall. APHA Stock VerdictIt's good that Aphria has cleaned house. That was a necessary and important first step in recovering the market's trust in Aphria going forward. But there's still a lot to be uncertain of.Particularly in a market where so many of the big leaders in the space have deals with credible partners, it's easy to take a pass on APHA stock. Cronos (NASDAQ:CRON) has Altria (NYSE:MO) while Canopy Growth (NYSE:CGC) has partnered with Constellation (NYSE:STZ). Meanwhile, Aurora (NYSE:ACB) doesn't have a major partner yet, but its management team hasn't given us any big reasons to doubt its credibility either.The marijuana stock sector is the Wild West right now. Many of the companies out there are going to crash and burn in coming years. Aphria's efforts to clean up their act are appreciated. But in such a risky sector, at least for the time being, it's advisable to stick to more trustworthy leaders in the cannabis space.At the time of this writing, Ian Bezek owned MO stock. You can reach him on Twitter at @irbezek. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Tech Stocks With Too Much Risk, Not Enough Upside * 7 Companies That Are Closing the CEO-Worker Wage Gap * 7 Video Game ETFs That Will Make You a Winner Compare Brokers The post After the Drama, Where Is Aphria Headed Now? appeared first on InvestorPlace.

  • This Is Why Canopy Growth Is the Best Pot Stock
    InvestorPlace9 hours ago

    This Is Why Canopy Growth Is the Best Pot Stock

    Ever since the cannabis craze hit Wall Street back in mid-2018, I've been pounding on the table saying that the best marijuana stock to buy in the group is Canopy Growth (NYSE:CGC). The logic is simple: In addition to being the biggest player in the industry, CGC stock has long had one thing that no other cannabis company has -- $4 billion in cash from Constellation Brands (NYSE:STZ).Source: Shutterstock That $4 billion gives Canopy unprecedented visibility into being one of the industry's long-term winners through early, aggressive, and large investments. As such, I have consistently reasoned that CGC stock belongs in every cannabis-related portfolio.This bull thesis got a big boost in mid-April. Canopy struck a deal with major U.S. cannabis operator Acreage to buy that company for $3.4 billion once cannabis is legalized nationwide in the U.S.InvestorPlace - Stock Market News, Stock Advice & Trading TipsFor those who don't follow this industry closely, that's a big deal. Canopy is the star player in the legal Canadian cannabis market. But the Canadian market is peanuts. The big deal here is the U.S. market. Depending on who you ask, that market is about tenfold the size of the Canadian market.Thus, the big question for Canopy and other Canadian pot stocks is whether or not these companies can replicate their success in the U.S. * 7 Strong Buy Stocks the Street Loves Canopy just answered that question in emphatic fashion, and the market is reacting favorably. CGC stock popped roughly 10% on the news.In the big picture, thanks to a $4 billion early investment from Constellation Brands, Canopy has given itself unprecedented visibility into being a long-term cannabis market leader. Right now, following the Acreage deal, that visibility is as strong as ever. Consequently, the long-term bull thesis for CGC is likewise as strong as ever. The Acreage Acquisition Is Big NewsThere's a reason CGC popped 10% in response to the company agreeing to acquire Acreage. In plain English, it positions the company to fully capitalize on the $100 billion U.S. cannabis market from the onset.First, some context. The whole Wall Street cannabis craze has been largely centered around one thing: the nationwide legalization of cannabis in Canada in late 2018. Roughly speaking, that single catalyst turned the big four Canadian pot stocks -- Canopy, Aurora (NYSE:ACB), Tilray (NASDAQ:TLRY) and Cronos (NASDAQ:CRON) -- from relatively unknown companies to Wall Street household names with multi-billion dollar market caps.But, while Canadian market legalization was the catalyst, it wasn't the prize. The prize here is the U.S. market, which most estimates put at a $100 billion opportunity, versus $10 billion in Canada. The consensus thesis is that, with cannabis fully legal throughout Canada and hemp legal throughout the U.S., it's only a matter of time before cannabis is fully legal across the entire U.S. The big question is whether or not Canadian cannabis giants like Canopy will be able to capitalize on the big U.S. opportunity when it comes knocking.Canopy just answered that question. By agreeing to acquire Acreage -- a major U.S. cannabis operator with dozens of dispensaries and cultivation sites across 20 states -- Canopy has positioned itself to capitalize on the $100 billion U.S. cannabis market opportunity from the onset. That is, as soon as cannabis is fully legal across the U.S., Canopy will be everywhere through Acreage -- and ready to dominate the U.S. market like it's dominated the Canadian market.That's a big deal. Indeed, it paves the path for CGC to head materially higher in a long-term window. Canopy Growth Stock Has Long-Term UpsideMy long-term bull thesis on Canopy Growth stock is that, if this company can successfully maintain its leadership position as the cannabis industry goes global and matures, then this is a $100 billion company in the making. With more visibility than ever to U.S. market domination, that long-term bull thesis looks about as good as ever.The details of my analysis behind the $100 billion number can be found here. But the short recap is pretty easy to understand. At scale, given current consumption trends, the recreational cannabis market could one day be as big as the alcoholic beverage and tobacco markets. What's more, if you consider the medical opportunity, then the aggregate global cannabis market will easily one day be as big as, if not bigger than, the alcoholic beverage and tobacco markets.The top dogs in those two industries have $100 billion-plus market caps. Witness Anheuser-Busch (NYSE:BUD) or Altira (NYSE:MO). Thus, it's only reasonable to assume that the top dogs in the global cannabis industry at scale will be $100 billion-plus companies too.Given its early leadership position, huge financial resources, aggressive management team, large growing capacity, and global distribution network, Canopy has all the tools necessary to turn into a top dog in the global cannabis industry in a decade. Now, Canopy also has visibility to be a top dog in the U.S. market. Thus, this company continues to take steps towards securing global leadership.So long as the company remains on that path, CGC stock will remain on an uptrend towards a $100 billion valuation. * 10 Dividend Growth Stocks You Can't Miss Bottom Line on CGC StockThere are a lot of pot stocks out there, but none of them have as much long-term visibility as Canopy Growth. Given this, if you're buying into the cannabis industry with a multi-year horizon, CGC stock is the best pick in the industry, without question.As of this writing, Luke Lango was long CGC and ACB. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 Dividend Stocks Perfect for Retirees * 7 Reasons the Stock Market Rally Isn't Over Yet * 10 S&P 500 Stocks to Weather the Earnings Storm Compare Brokers The post This Is Why Canopy Growth Is the Best Pot Stock appeared first on InvestorPlace.

  • Market Exclusive9 hours ago

    Canopy Growth Acquires Spanish Cannabis Producer Cafina

    Canopy Growth (TSX: WEED) (NYSE: CGC) completed an all-cash acquisition of Spain-based licensed cannabis producer Cáñamo y Fibras Naturales S.L. (Cafina). Financial terms of the deal were not disclosed. Canopy Eyes European Market Canopy said that the acquisition provides it the foundation to expand its European production footprint into one of the most ideal-growing regions […]The post Canopy Growth Acquires Spanish Cannabis Producer Cafina appeared first on Market Exclusive.

  • Monday’s Vital Data: Pfizer, Canopy Growth Corp and Microsoft
    InvestorPlace9 hours ago

    Monday’s Vital Data: Pfizer, Canopy Growth Corp and Microsoft

    U.S. stock futures are trading lower as traders return from the Easter holiday weekend.Ahead of the bell, futures on the Dow Jones Industrial Average are down 0.39%, and S&P 500 futures are lower by 0.40%. Nasdaq-100 futures have shed 0.57%.In the options pits on Thursday, call volume led the charge, and overall volume levels ended slightly above average. Specifically, about 20.5 million calls and 17.9 million puts changed hands on the session.InvestorPlace - Stock Market News, Stock Advice & Trading TipsHowever, those calls didn't translate over to the CBOE, where the single-session equity put/call volume ratio ramped to 0.62 -- a one-week high. Meanwhile, the 10-day moving average held steady at 0.60.Here are three popular stocks landing atop the most-active options list: Pfizer (NYSE:PFE), Canopy Growth Corp (NYSE:CGC) and Microsoft (NASDAQ:MSFT).Let's take a closer look: Pfizer (PFE)Weakness in the healthcare sector spilled into biopharma. Pfizer fell 6.4% over the final three trading sessions of the week to close at a new nine-month low. The groundswell in volume during Friday's swoon revealed panic was in the air and could help to spell a short-term low in the now deeply oversold stock.But with PFE submerged deeply beneath all major moving averages, expect any relief rally to be short-lived. * 10 Best Stocks to Buy and Hold Forever The next earnings release is slated for April 30.On the options trading front, puts ruled the roost. Activity jumped to 417% of the average daily volume, with 129,626 total contracts traded. Puts edged out calls to claim 53% of the day's take.The increased demand drove implied volatility higher on the day to 26%, placing it at the 60th percentile of its one-year range. Premiums are officially juiced and no price in daily moves of 65 cents or 1.7%. Canopy Growth Corp (CGC)Canopy Growth Corp shares saw heightened volatility on Thursday after the company reported a deal giving it the right to buy Acreage Holdings (OTCMKTS:ACRGF). Acreage Holdings operates in the U.S., and its purchase will allow CGC to expand into the country if the federal government ever decides to legalize cannabis.The initial surge on the news carried CGC stock up as much as 11.4%. However, by day's end, profit-taking pared the gain to 3.9%. For the past two months, Canopy Growth Corp shares have been locked in a trading range. Thursday's jump had the potential to finally break the stock out, but the substantial amount of selling that came in near resistance rejected the attempt. Until we see a proper breach of the ceiling at $47.50, CGC remains a tricky trade.On the options trading front, traders gobbled up call options. Total activity grew to 315% of the average daily volume, with 133,768 contracts traded; 71% of the trading came from call options alone.Implied volatility popped on the day to 56%, but remains near the lower end of its one-year range. Microsoft (MSFT)The technology sector has been a standout in recent months, and Microsoft is arguably the poster child for its strength. MSFT stock surged to a new record high on Thursday, bringing its year-to-date gains to 21.6%. The profits come as investors gear up for the software sultans next earnings release on April 24.The catalyst for Thursday's euphoria was Microsoft announcing its purchase of Express Logic.On the options trading front, calls outpaced puts by a wide margin. Activity climbed to 224% of the average daily volume, with 285,449 total contracts traded; 67% of the trading came from call options alone.Implied volatility remains at the low end of its range, which suggests investors have little fear heading into earnings. At 24%, implied volatility sits at the 20th percentile of its one-year range. Premiums are baking in daily moves of $1.85 or 1.5%.As of this writing, Tyler Craig didn't hold a position in any of the aforementioned securities. Check out his recently released Bear Market Survival Guide to learn how to defend your portfolio against market volatility. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Tech Stocks With Too Much Risk, Not Enough Upside * 7 Companies That Are Closing the CEO-Worker Wage Gap * 7 Video Game ETFs That Will Make You a Winner Compare Brokers The post Monday's Vital Data: Pfizer, Canopy Growth Corp and Microsoft appeared first on InvestorPlace.

  • Cannabis Stock Canopy Growth (CGC) Could Race Above $60, but Caution Is Warranted
    SmarterAnalyst9 hours ago

    Cannabis Stock Canopy Growth (CGC) Could Race Above $60, but Caution Is Warranted

    Only a few days after Canopy Growth (CGC) acquired a Spanish licensed cannabis producer, the company has announced a proposed deal to enter the U.S. market via the right to purchase Acreage Holdings (ACRGF) in the future. The move has high hopes for the U.S. government to approve cannabis at the federal level and makes the multi-state operators (MSOs) in the U.S. as the most attractive stocks going forward.A Right That Might Not HappenDue to listing requirements by the Toronto Stock Exchange and the NYSE, listed companies can’t own illegal operations. Since cannabis is illegal at the federal level, Canopy Growth is prevented from owning a U.S. cannabis company. The recent Farm Bill allows the company to enter the hemp market and CBD, but not pot.For this reason, Canopy Growth has to make a deal that involves the right to purchase Acreage once federally approved. The company is paying $3.4 billion to buy Acreage with an upfront cost of $300 million for this future right.The deal involves a $2.55 per share upfront payment to investors for waiting plus an agreement to receive 0.5818 shares of Canopy Growth once the deal closes. At the current stock price of $46, Acreage shareholders have a right to a Canopy Growth stock worth $26.76 plus the $2.55 payment. The stock only trades right above $23 on the deal.The problem for shareholders is that the outcome is unknown. The U.S. is likely to approve cannabis in the future, but no guarantee exists. Not to mention, where Canopy Growth trades at that point is another high risk as the company has aggressive global expansion plans such as the recent deal in Spain.Other U.S. MSOs. While Acreage is listed as a leading MSO in the U.S., the company trails other companies like Harvest Health & Recreation (HRVSF). Acreage is listed as having agreements for cannabis-related licenses in 20 states with rights to 87 dispensaries and 22 cultivation and processing sites.Harvest Health has a deal pending with Verano that gives the combined company the right operate up to 200 facilities in 16 states with 123 dispensaries. Harvest Health expects to have 70 dispensaries and 26 cultivation and manufacturing facilities open by the end of 2019.The backing of Constellation Brands (STZ) provides Canopy Growth with the cash and shares to promote Acreage to offer up to $1.4 billion worth of shares for future acquisitions. The proposal suggests that the company will look to rollup smaller companies during the waiting period likely placing a premium value on sub $1 billion cannabis companies in the U.S.TakeawayThe key investor takeaway is that Canopy Growth is making the anticipated splash to enter the U.S. cannabis market, though via a highly delayed right to buy Acreage in the future. Investors shouldn’t expect other U.S. MSOs to accept similar deals in the future with such deals locking in values based on current prices.Canopy stock went up on the news and could breakout to new all-time highs above $60. Regardless, the better stocks remain the pure plays on the U.S. cannabis market. Acreage is now on the acquisition trail and the inevitable U.S. entry by the other large Canadian LPs either via similar rights to purchase deals or once the cannabis if federally legal will make the U.S. companies more valuable.To read more on the nitty gritty of what’s going on in the rising cannabis industry, click here. Disclosure: The author has no position in Canopy Growth stock.Read more on CGC: * Canopy Growth (CGC): Piper Jaffray Wishes Upon a Marijuana Star (But Will Its Dreams Come True?) * Canopy Growth (CGC): Is This Spanish Acquisition Too Good to Be True? * Canopy (CGC): Seaport Cuts Estimates, Reiterates Neutral on the Cannabis Stock More recent articles from Smarter Analyst: * Wedbush Sets Expectations on Twitter (TWTR) Stock Ahead of Q1'19 Earnings * Cannabis Stock CannTrust (CTST) Reported Key Metrics that Give Investors Insight Into Q1'19 Results * MKM Continues to Recommend Micron (MU) Stock; Here's Why * Advanced Micro Devices (AMD) Stock Is Back in a Big Way

  • MarketWatch10 hours ago

    Canopy upgraded to buy at GMP after clinching Acreage deal

    Canopy Growth Corp. was upgraded to buy from hold on Monday by analyst Martin Landry at GMP, after the company last week bought the rights to acquire U.S. multi-state operator Acreage Holdings Inc. as soon as cannabis is legalized in the U.S. "This transaction should boost Acreage's ability to consolidate the US market," Landry wrote in a note to clients. "Hence, when Canopy officially takes ownership of Acreage, it could be much larger than currently." The deal gives Canopy a foothold in the U.S. market, which is estimated at about $10 billion, or 10 times larger than Canada, which fully legalized cannabis last October. Acreage is already in 20 states with 87 dispensaries and 22 cultivation and processing sites. Canopy is paying $3.4 billion, equal to a valuation multiple of 21.5 times consensus EBITDA for 2020. "In our view, this takeout multiple is low given the strategic nature of the acquisition and the potential for continued strong growth as 2021 consensus estimates forecast Acreage's EBITDA to double over 2020," Landry wrote. "Furthermore, valuations of MSOs are likely to be higher upon legalization." The analyst raised his stock price target by $7 to $72, or about 21% above its current trading level. U.S.-listed shares rose 1.8% in premarket trade and have gained 89.3% in the last 12 months, while the S&P 500 has gained 8.5%.

  • Market Exclusive10 hours ago

    Constellation Brands, Canopy Growth Sign Deal To Revise Warrants

    Constellation Brands, Inc. Class A (NYSE:STZ) and Canopy Growth Corp (NYSE:CGC) have announced that they have agreed to make some changes to various warrants and rights. The new agreement to change some of the warrants and rights that influence their partnership is believed to have been influenced by Canopy’s plans to acquire Acreage Holdings Inc […]The post Constellation Brands, Canopy Growth Sign Deal To Revise Warrants appeared first on Market Exclusive.

  • Tweed and TerraCycle team up to take Cannabis Packaging Recycling Program across Canada
    PR Newswire10 hours ago

    Tweed and TerraCycle team up to take Cannabis Packaging Recycling Program across Canada

    SMITHS FALLS, ON, April 22, 2019 /PRNewswire/ - In the spirit of Earth Day, Canada's best-known cannabis brand is thrilled to officially launch the Tweed x TerraCycle recycling program across Canada. Previously available in select stores and provinces, today's announcement officially marks the roll out of Canada's first country-wide Cannabis Packaging Recycling Program. As we approached legalization of recreational cannabis in Canada, Tweed realized a solution was needed for all the new containers, tubes and packages in our industry, to ensure they are diverted away from landfills and upcycled into other products.

  • Why These Are the Top 2 Pot Stocks to Buy Right Now
    InvestorPlace13 hours ago

    Why These Are the Top 2 Pot Stocks to Buy Right Now

    One of the big themes in the cannabis sector in 2019 has been increased Wall Street coverage. Specifically, Wall Street firms were largely unwilling to cover cannabis stocks in 2018 given the industry's relative newness, rampant investor speculation and lack of fundamental tangibility. But, things have changed for marijuana stocks in 2019. The industry is less new. There's less speculation. The fundamentals have become significantly more tangible. As such, Wall Street firms have more broadly launched coverage on pot stocks in 2019.Source: Shutterstock One big firm that just initiated coverage on pot stocks is Bank of America. Their take? Of the Big Four pot stocks -- Canopy Growth (NYSE:CGC), Aurora Cannabis (NYSE:ACB), Cronos Group (NASDAQ:CRON) and Tilray (NASDAQ:TLRY) -- the only two worth buying right now are Canopy and Aurora.This isn't an isolated viewpoint. According to TipRanks data, 10 analysts cover CGC stock, while eight analysts cover ACB stock. Of those 18 ratings between CGC and ACB, none of them are Sell ratings. Instead, the consensus rating on CGC stock is "Moderate Buy" while on ACB stock, it's "Strong Buy."InvestorPlace - Stock Market News, Stock Advice & Trading TipsMeanwhile, a third of the nine analysts who cover CRON stock have a "Sell" rating on the shares. The consensus rating is a "Hold." Half of the 10 analysts that cover TLRY stock have a "Sell" rating on the name. The consensus rating on TLRY is a "Hold," too.In other words, the broad consensus among Wall Street firms is that when it comes to the cannabis space, investors should buy CGC and ACB, and forget about CRON and TLRY for the time being. I largely agree with consensus Wall Street view. Here's why. Why Buy CGC Stock?The plain answer here is you buy CGC stock because this company has the most visibility today among all pot stocks to one day transform into a long term market leader. * 7 High-Risk Stocks With Big Potential Rewards Canopy has everything you'd want in an early-stage leader in a big-growth market. Sales leadership? They dwarf everyone else in the space when it comes revenues. Growth? They are growing just about as fast as anyone in the space, despite a much bigger base. Production leadership? They sell far more kilograms of cannabis than anyone else, and have among the largest production footprints in the world. Market expansion? They are pushing aggressively into the U.S. hemp market. Confident leadership? CEO Bruce Linton just said that Canopy will generate over C$1 billion ($748 million) in sales over the next 12 months. Celebrity connections? They have ties with Seth Rogen, Snoop Dogg, and Martha Stewart.Above all else, though, Canopy has the financial resources and firepower to sustain and even grow its early lead. A few quarters ago, alcoholic beverage giant Constellation Brands (NYSE:STZ) poured $4 billion into Canopy. The company still has $3 billion of that left on the balance sheet. That's almost double what any of its competitors have in terms of cash on hand.While 2018 saw a blockbuster year (with nearly $14 billion raised) for cannabis investments, 2019 is on pace to blow past that total, according to cannabis research provider New Frontier Data. Click to EnlargeThus, Canopy has far more firepower than anyone else in this space to invest in growth opportunities, expand operations, expand production, acquire smaller players, so on and so forth. As such, the company does reasonably project as a long-term leader in the global cannabis market, and that's why buying CGC stock today makes sense. Why Buy ACB Stock?The plain answer here is you buy ACB stock because this is the cheapest pot stock in the group for reasons that are most likely temporary.On a pure valuation basis, ACB stock is as cheap as it gets in the cannabis space. Across every metric -- trailing sales, forward sales, market cap per kilogram, annualized revenue -- ACB stock is considerably cheaper than its peers. We are talking a 20%+ undervaluation gap. * 7 Stocks to Buy for Spring Season Growth This relative undervaluation has nothing to do with operating fundamentals. Aurora is big, with the second-largest sales base in the market behind Canopy. The company controls about 20% of the Canadian adult-use market. They also have tremendous production capacity (Aurora has 500,000 kilograms per year in funded capacity) and gross profit margins are among some of the healthiest in the business.Instead, the relative undervaluation in ACB stock has to do with balance sheet. Specifically, unlike peers Canopy and Cronos, Aurora hasn't scored a big investment from a consumer staples giant. Thus, the balance sheet isn't overflowing with billions of dollars to help fund growth. Instead, Aurora has just over $100 million in cash on hand.This won't last forever. Aurora is a big and leading company in the rapid growth cannabis space. The stock is also trading at a huge discount to peers. Thus, it truly is only a matter of time before some big consumer staples company pumps a billion bucks in here, or more. When that happens, the relative undervaluation gap will disappear, and ACB stock will rally in a big way. Bottom Line on CGC Stock and ACB StockThe cannabis sector reeks of long-term potential. But, a lot will happen between now, and when the market matures, and that means that investors need to choose wisely when investing in pot stocks this early in the game.Investment translation? Only buy CGC stock and ACB stock. There are very good reasons to own those two pot stocks here and now, and they should rally over the next several quarters.As of this writing, Luke Lango was long CGC and ACB. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 Dividend Stocks Perfect for Retirees * 7 Reasons the Stock Market Rally Isn't Over Yet * 10 S&P 500 Stocks to Weather the Earnings Storm Compare Brokers The post Why These Are the Top 2 Pot Stocks to Buy Right Now appeared first on InvestorPlace.

  • Market Exclusive17 hours ago

    Cannabis Stock News Daily Roundup April 22

    Nabis, a California's cannabis distributor, has raised $4 million during their second round of financing. This follows their seed round last summer when they raised $1.25 million from Silicon Valley's elite investors, bringing the total amount raised to $5.25 million since its inception in 2017. Aphria (TSX: APHA) (NYSE: APHA) said that its German subsidiary Aphria […]The post Cannabis Stock News Daily Roundup April 22 appeared first on Market Exclusive.

  • 3 Crazy Facts About Canopy Growth's Largest Acquisition in Marijuana History
    Motley Foolyesterday

    3 Crazy Facts About Canopy Growth's Largest Acquisition in Marijuana History

    Canopy's $3.4 billion purchase of Acreage Holdings is unlike anything Wall Street or investors have ever seen.

  • Benzinga2 days ago

    Harvest Health CEO Steve White Talks Cannabis Consolidation, Says Canopy-Acreage Tie-Up 'Fantastic'

    Harvest Health & Recreation, Inc. (OTC: HRVSF ) CEO Steve White joined Yahoo's Jeff Lagerquist onstage Thursday at the Benzinga Cannabis Capital Conference to discuss consolidation in the marijuana industry.  ...

  • Cannabis stocks pare early gains as Canopy secures future foothold in the U.S.
    MarketWatch2 days ago

    Cannabis stocks pare early gains as Canopy secures future foothold in the U.S.

    Cannabis stocks rallied on Thursday before paring their gains, boosted by the news that the biggest company in the sector by market cap has bought the rights to acquire a U.S. multistate operator as soon as the federal ban on cannabis has been lifted.

  • Corona and Canopy: A mix of beer and pot that could juice your stock portfolio
    MarketWatch2 days ago

    Corona and Canopy: A mix of beer and pot that could juice your stock portfolio

    Constellation Brands is boosting its U.S. beer business while betting that marijuana products will deliver big sales.

  • Barrons.com3 days ago

    Marijuana Stocks Take the Long-Term View. But Expect ‘Teething’ Problems.

    Investor interest in marijuana stocks led Jefferies to hold its first cannabis conference, featuring 30 companies and 260 investors. Here are a few things that marijuana companies are thinking about for the long-term.